Friedreich ataxia (FA) is a rare inherited disease that affects the nervous system. It is usually diagnosed in childhood and affects about 5,000 people in the U.S. It causes a loss of muscle control.

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical ...

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its ...

Please provide your email address to receive an email when new articles are posted on . Skyclarys was approved in the U.S. for Friedreich’s ataxia in 2023. Approval was based on positive results from ...

IntraBio Inc. today announced the submission of a variation application to the European Medicines Agency (EMA) to expand the approved Marketing Authorization Application (MAA) for AQNEURSA® ...

CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended ...

Apraxia is a neurological disorder that affects the mental processes involved in planning, task performance, and more. Ataxia is a neurological sign affecting muscle coordination and movement.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cerebellar ataxia results from dysfunction of the cerebellum, which is part of the brain that helps regulate and control movement and balance. People may experience changes in gait, speech, and eye ...

Today, we celebrate the impact of an engaged patient community, and we are grateful to the FDA and Reata for working together on the approval of SKYCLARYS, the first therapy approved in the United ...

“In my clinical practice, I have seen the devastating impact that Friedreich’s ataxia has on patients and their families,” said Sylvia Boesch, M.D., MSc, Principal Investigator of the MOXIe study and ...